Patritumab Deruxtecan

June 18, 2025 7:00 am ET BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada. While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in the advanced or metastatic stage.1 Current standard of care for patients with mCRPC includes treatment with androgen receptor pathway inhibitors followed by taxane-based chemotherapy.2-5 However, due to poor prognosis associated with previously treated mCRPC, many patients do not receive subsequent therapy, reinforcing the need for new approaches to improve outcomes.6 “Despite the emergence of new therapies, the current treatment landscape for patients with metastatic castration-resistant prostate cancer is challenging, and there is a need for new treatments,” said Mark Rutstein, MD, Head, Therapeutic Area Oncology Development, Daiichi Sankyo. “Following the promising results seen in our earlier phase trial, IDeate-Prostate01 has been initiated to evaluate whether ifinatamab deruxtecan may replace standard taxane-based chemotherapy as a potential treatment strategy in patients with metastatic castration-resistant prostate cancer with disease progression during or after treatment with androgen receptor pathway inhibitors.” “IDeate-Prostate01 marks the initiation of the third pivotal trial in the ifinatamab deruxtecan development program and reinforces our commitment to addressing critical unmet needs for patients,” said Marjorie Green, MD, Senior Vice President and Head of Oncology, Global Clinical Development, Merck Research Laboratories. “Our continued progress in the exploration of this potential first-in-class B7-H3 antibody drug conjugate in collaboration with Daiichi Sankyo, speaks to our pursuit of novel science in the hopes of making a difference for patients in need of new options.” The initiation of IDeate-Prostate01 is based on results from the IDeate-PanTumor01 phase 1/2 trial previously presented at the 2022 and 2023 European Society of Medical Oncology (ESMO) Congresses where ifinatamab deruxtecan showed promising responses in heavily pretreated patients with mCRPC. About the IDeate-Prostate01 Trial IDeate-Prostate01 is a multicenter, open-label, randomized phase 3 trial evaluating the safety and efficacy of ifinatamab deruxtecan (12 mg/kg) versus docetaxel (75 mg/m2) plus corticosteroid in patients with mCRPC. Eligible patients must have received prior treatment with one or two androgen receptor pathway inhibitors and experienced disease progression during or after at least eight weeks of treatment. The dual primary endpoints of IDeate-Prostate01 are overall survival and radiographic progression-free survival. Secondary endpoints include objective response rate, time to first subsequent therapy, duration of response, time to pain progression, time to prostate-specific antigen (PSA) progression, PSA response, time to first symptomatic skeletal-related event and safety. IDeate-Prostate01 will enroll approximately 1,440 patients across Asia, Europe, North America and Oceania. For more information, please visit ClinicalTrials.gov. About Metastatic Castration-Resistant Prostate Cancer Prostate cancer is the second most common cancer in men, and the fifth leading cause of cancer death in men worldwide.7 Nearly 1.5 million prostate cancer cases were diagnosed in 2022, with approximately 400,000 deaths globally.7 While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in advanced or metastatic stage.1 Approximately 10% to 20% of early-stage prostate cancer cases progress to metastatic disease within five years of treatment on hormonal therapies such as androgen deprivation therapy.8,9 Current standard of care for patients with mCRPC includes treatment with androgen receptor pathway inhibitors followed by taxane-based chemotherapy. However, due to poor prognosis associated with previously treated mCRPC, many patients do not receive subsequent therapy, reinforcing the need for new approaches to improve outcomes.6 About B7-H3 B7-H3 is a transmembrane protein that belongs to the B7 family of proteins, which bind to the CD28 family of receptors that includes PD-1.10,11 B7-H3 is overexpressed in a wide range of cancer types, including mCRPC and its overexpression has been shown to correlate with poor prognosis, making B7-H3 a promising therapeutic target.12-15 There are currently no B7-H3 directed medicines approved for the treatment of any cancer. About Ifinatamab Deruxtecan Ifinatamab deruxtecan (I-DXd) is an investigational potential first-in-class B7-H3 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ifinatamab deruxtecan is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Ifinatamab deruxtecan has been granted orphan drug designation by the U.S. Food and Drug Administration, European Commission, Japan Ministry of Health, Labour and Welfare and Taiwan Food and Drug Administration for the treatment of small cell lung cancer. About the Ifinatamab Deruxtecan Clinical Development Program A comprehensive global clinical development program is underway evaluating the efficacy and safety of ifinatamab deruxtecan across multiple B7-H3 targetable cancers. Trials in combination with other anticancer treatments also are underway. About the Daiichi Sankyo and Merck Collaboration Daiichi Sankyo and Merck entered into a global collaboration in October 2023 to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd), except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply. In August 2024, the global co-development and co-commercialization agreement was expanded to include gocatamig (MK-6070/DS3280), which the companies will jointly develop and commercialize worldwide, except in Japan where Merck will maintain exclusive rights. Merck will be solely responsible for manufacturing and supply for gocatamig. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo. The ADC platform furthest in clinical development is Daiichi Sankyo’s DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU®, a HER2 directed ADC, and DATROWAY®, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo. The second consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform. Ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical needs. For more information, please visit www.daiichisankyo.com. Merck’s Focus on Cancer Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). References: Media Contacts: Merck Julie Cunningham (617) 519-6264 julie.cunningham@merck.com Michael McArdle (908) 447-9453 michael.mcardle@merck.com Daiichi Sankyo Global/US Media: Jennifer Brennan jennifer.brennan@daiichisankyo.com (908) 900-3183 Japan Media: DS-PR@daiichisankyo.co.jp Investor Contacts: Merck Peter Dannenbaum (732) 594-1579 peter.dannenbaum@merck.com Steven Graziano (732) 594-1583 steven.graziano@merck.com Daiichi Sankyo DaiichiSankyoIR_jp@daiichisankyo.com

今年的美国临床肿瘤学会（ASCO）会议聚焦于乳腺癌、胃癌、肺癌和头颈癌领域具有改变临床实践意义的研究成果，并重点关注了大型制药公司研发的新一代抗体药物偶联物（ADC）。以下是对会议内容的报道和分析：口服 SERDs 在 ER + 乳腺癌中的竞争在ASCO全体会议上，阿斯利康（AstraZeneca）展示了其口服选择性雌激素受体降解剂（SERD）camizestrant在ER 阳性 / HER2 阴性乳腺癌中的一线转换策略数据。III期SERENA-6 研究显示，在接受芳香化酶抑制剂和 CDK4/6 抑制剂标准治疗期间出现ESR1突变的患者中，换用 camizestrant 联合相同 CDK4/6 抑制剂后，疾病进展或死亡风险降低56%。然而，并非所有人都认可阿斯利康的连续循环肿瘤DNA（ctDNA）的监测方案。礼来肿瘤（Lilly Oncology）领域总裁Jacob Van Naarden强调了连续液体活检带来的经济、后勤和心理负担，然而其竞品口服 SERD imlunestrant 在III 期 EMBER-3 试验中无需复杂的监测流程即可实现相似的疾病控制持续时间。乳腺癌领域：Enhertu再获突破在乳腺癌领域的另一项突破中，阿斯利康与第一三共（Daiichi Sankyo）的 Enhertu（曲妥珠单抗德鲁替康），在转移性 HER2 阳性乳腺癌治疗领域大显身手。III 期 DESTINY-Breast09 研究结果显示，Enhertu 联合罗氏的 Perjeta（帕妥珠单抗）中位无进展生存期（PFS）达 40.7 个月，较标准治疗 Herceptin（曲妥珠单抗）+ Perjeta 延长超1年。Imfinzi 在胃癌围手术期治疗成功阿斯利康的III期MATTERHORN研究，有望为 Imfinzi（度伐利尤单抗）开辟又一重磅适应症。PD-L1抑制剂Imfinzi（durvalumab）联合FLOT化疗用于早期胃癌/胃食管结合部癌的围手术期治疗中，Imfinzi 改善了早期胃癌和胃食管交界癌患者的无事件生存期，而 Keytruda（帕博利珠单抗）此前在此领域未能成功。未来需聚焦的两个关键问题在于：对于微创或无淋巴结转移患者，该方案的获益风险比如何？以及疾病进展后的后续治疗顺序如何优化？默克 HER3靶向ADC 在非小细胞肺癌（NSCLC）中失利随着 Keytruda 专利到期日益临近，Merck& Co.的 HER3靶向ADC药物 patritumab deruxtecan 在总生存期（OS）上的失败及其撤回的监管申请更是雪上加霜。III 期 HERTHENA-Lung02 验证性研究数据显示，在 EGFR 突变的 NSCLC 患者中，三线治疗使用该 HER3 导向 ADC 的中位OS为16个月，与化疗组的15.9个月相比无显著差异，并导致两例致命性间质性肺病。默克正评估是否可通过生物标志物定义的亚组为 patritumab deruxtecan 在肺癌中寻找出路，并转向乳腺癌领域（计划今年启动III期研究）。Opdivo 挑战 Keytruda，在新诊断头颈鳞癌（HNSCC）中崭露头角ASCO 会前，Keytruda 围手术期治疗的 III 期 KEYNOTE-689 研究阳性结果提高了新诊断头颈鳞癌患者设定了更高标准。并可能挑战Keytruda在该领域的领先地位。礼来、艾伯维和默克展示新一代 ADC尽管 Enhertu 在现有获批 ADC中占据领先地位，但各大药企仍在加速布局：礼来：公布了其领先 ADC 药物 LY4170156 的首次人体试验数据，在晚期卵巢癌患者中总缓解率（ORR）达 55%。该候选药物靶向叶酸受体α（FRα），直接与艾伯维的 Elahere（mirvetuximab soravtansine）和 Genmab 的 rinatabart sesutecan（Rina-S）形成竞争。艾伯维：低调拓展其内部 ADC 平台，在会议上分享了 cMET 靶向 ADC 药物 telisotuzumab adizutecan（Temab-A）的I期数据，其在 EGFR 突变 NSCLC 患者三线治疗中 ORR 达 63%。默克：ASCO 的表现因 patritumab deruxtecan 的生存数据失利而蒙上阴影，但其管线中的其他ADC仍有早期积极数据，包括TROP2靶向ADCsacituzumab tirumotecan（sac-TMT）和 ROR1 靶向 ADC zilovertamab vedotin。信息来源：Pharma Industry News and Analysis | FirstWord Pharma药事纵横投稿须知：稿费已上调，欢迎投稿